Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Raises $50 Million to Launch Drugs in China

publication date: Mar 20, 2018

CASI Pharma, a Maryland-Beijing company, announced a $50 million private placement, which it will use to launch its first commercial product in China and supply working capital. Two months ago, CASI acquired a portfolio of 29 generic drug candidates from Sandoz, the generic drug division of Novartis. CASI plans to select certain members of the portfolio to develop for China approval. More details....

Stock Symbols: (NSDQ: CASI) (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China